Harrow, Inc. Gain (Loss) on Disposition of Intangible Assets
Harrow, Inc. (HROW) reported Gain (Loss) on Disposition of Intangible Assets of -$253.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnDispositionOfIntangibleAssets · last filed 2026-03-02
- Harrow, Inc. gain (loss) on disposition of intangible assets for the quarter ending 2023-12-31 was -$358.00K.
- Harrow, Inc. gain (loss) on disposition of intangible assets for fiscal 2024 was -$253.00K.
- Harrow, Inc. gain (loss) on disposition of intangible assets for fiscal 2023 was -$380.00K, a 155.39% decline from fiscal 2022.
- Harrow, Inc. gain (loss) on disposition of intangible assets for fiscal 2022 was $686.00K.
| Period end | Gain (Loss) on Disposition of Intangible Assets 3 month | Gain (Loss) on Disposition of Intangible Assets 9 month | Gain (Loss) on Disposition of Intangible Assets 12 month |
|---|---|---|---|
| 2024-12-31 | -$253.00K 10-K · filed 2026-03-02 | ||
| 2023-12-31 | -$358.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$380.00K 10-K · filed 2026-03-02 | |
| 2023-09-30 | -$22.00K 10-Q · filed 2024-11-14 | ||
| 2022-12-31 | $686.00K 10-K · filed 2024-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |